Air India has launched a drug-testing programme for all pilots that exceeds existing regulatory requirements [1, 2].
The move follows heightened safety scrutiny after a flight from Phuket to Delhi experienced a sudden drop in altitude, raising concerns about cockpit safety and pilot impairment.
The incident occurred on Aug. 4, 2024 [3]. During the flight, the aircraft lost approximately 300 feet in altitude [3]. Reports indicate that the captain of that flight tested positive for psychoactive substances [4, 5].
In response, the airline announced a testing programme in early August 2024, with mandatory screening for all pilots beginning on Aug. 13, 2024 [6]. While some reports describe the launch as a voluntary initiative by the company, other sources said the enhanced screening is now mandated for the entire pilot workforce [1, 2].
The screening process has already identified several pilots. Two pilots were initially flagged during preliminary drug screenings and were taken off duty while awaiting confirmatory tests [7]. Subsequently, two additional pilots failed drug screening tests [6].
The new protocols exceed the norms set by the Directorate General of Civil Aviation (DGCA) [2]. The airline is implementing these measures to ensure stricter adherence to safety standards and to prevent future occurrences of substance-related impairment in the cockpit [1, 2].
Air India has not provided further details on the specific substances detected or the disciplinary actions taken against the pilots who failed the tests.
“The airline launched an enhanced screening programme for all pilots following a mid-air altitude loss.”
This shift toward internal mandates that exceed national regulatory standards suggests a crisis of confidence in existing oversight. By implementing more rigorous screening, Air India is attempting to mitigate legal and reputational risks following a high-profile safety lapse, while signaling to international regulators that it is taking proactive steps to ensure flight crew sobriety.
